March 9 #BullshitBob announces 2016 full year losses, what will they be?

Quote
Should we all be looking for jobs? I know sometimes that the posts on this website are bs, but how much validity is there to the claims that we will only be around another 6 months?

I think Sprix is doing well, but I'm worried as a rep that could be one of the ones selling just Oxaydo and Aramo. 8 scripts a week does not make a profitable company
 






There's enough money to keep the company going for year. #BullshitBob is going to be dribbling lie after lie tomorrow morning so I'm interested to see if the shareholders and Board will have the guts to fire his sorry ass along with #ShiftyStan and #DrEvilDyno.

The loss will be over $100 million.
 






in all honesty, we can not survive for more than a year. we've been losing money, quarter by quarter since this commercial team was launched with our saving grace being, "just wait till Arymo gets here then we'll turn it around." Well Arymo is here and she is not the prom queen we thought she would be. She is a big fat cow and she is UGLY (referring to the labeling).

anonymous said:
Should we all be looking for jobs? I know sometimes that the posts on this website are bs, but how much validity is there to the claims that we will only be around another 6 months?

I think Sprix is doing well, but I'm worried as a rep that could be one of the ones selling just Oxaydo and Aramo. 8 scripts a week does not make a profitable company
Click to expand...
 






Yep, things here in Wayne have been under wraps. Stan and his crew are tight lipped. The mood is low (morale's been in the shitter since October and plunged even more after the labeling screw up in January). Rumor is that Bob and Mark will be gone by the end of the first quarter. The securities fraud will end his career.

Everyone expects the losses to be well over $100 million. How can any small company sustain that?
 












anonymous said:
Yep, things here in Wayne have been under wraps. Stan and his crew are tight lipped. The mood is low (morale's been in the shitter since October and plunged even more after the labeling screw up in January). Rumor is that Bob and Mark will be gone by the end of the first quarter. The securities fraud will end his career.

Everyone expects the losses to be well over $100 million. How can any small company sustain that?
Click to expand...

I can't wrap my head around the idea of a company of this size sustaining a loss like this. How can you afford to pay employees without sales?
 






"Net loss for the year ended December 31, 2016 was $90.6 million, or $3.70 per share, compared to a net loss of $57.9 million, or $2.94 per share, for the year ended December 31, 2015. The net loss for the quarter ended December 31, 2016 was $21.4 million, or $0.87 per share, compared to a net loss of $6.8 million, or $0.28 per share, for the quarter ended December 31, 2015."

So folks - we've nearly DOUBLED our losses in a year.....:(
 






Ouch! I just read the transcript from this morning's analyst meeting. Radie got crucified by Goldman Sachs. They were calling for a management change including him! Based on lack of all around performance - no credibility, neglible sales, massive losses, class action suits for securities fraud and the disastrous FDA Arymo announcement. He's out..... Soon.
 






During the conference call's Q&A session, an analyst named Christina Hung from Goldman Sachs posed a rather direct, if not rude question. While this in itself may not necessarily be unheard of, Seeking Alpha's transcript of the call shows that Goldman Sachs stated the analyst's "employment has not been verified."

The Question
The analyst asked Egalet's management to justify its "negligible" sales of $20 million and $100 million losses in a market worth over $12.5 billion. Moreover, the person added that the company's U.S. Food and Drug Administration's approval of ARYMOA was a "disaster" which lead to the question to the company's CEO Robert Radie, "Don't you think it's time for management change, including yourself?"
 






#thankyouchristina

Christina Hung

Yes, hi, Bob, thank you for taking my call. So 2016 was a challenging and pivotal year, however Egalet did less than $20 million of sales in a market worth over $12.5 billion that's negligible. You lost nearly $100 million. The ARYMO FDA approval announcement was a disaster and your shares are trading at an all time low. But you have dozens of transaction lawsuits against you. Don't you think it's time for management change including yourself?

Bob Radie

Christina, I appreciate the question obviously when you paint things that way it sounds all gloom and doom but I think we look at things quite differently here in terms of our revenue projections. We have actually grown consistently quarter-over-quarter. We are continuing to move our established products forward which we're very, very excited about. We believe that the introduction of ARYMO and the approval of ARYMO is a significant advancement for the company it validates the Guardian Technology and everything that we believed in. I can always understand how markets react to certain things, I think having a product approved is a big step forward for the company, it validates the technology. We believe that ARYMO wouldn't has not lost one day of its long-term revenue potential for this product. So we will continue to run the business the way we believe is the right way to run the business and we appreciate your question.

Christina Hung

Is there anything you can say to give us confidence in your credibility moving forward?

Bob Radie

This is a very experienced management team. We have all been part of a lot of different companies before and so we are going to continue to execute on our strategy and do everything that we can to be successful. Thank you
 






anonymous said:
Some analysts are bullish. Having been a TM for just over a year I don't think that management suck any more than any other pharma company. Bob doesn't deserve any awards, he has no credibility here. Sprix and Oxyado are a hard sell but Arymo will do well. We're allowed to point out to docs the ad board advisory vote that the product deters abuse through all major routes. So that's a plus.

Sales still suck and marketing is way off base, especially Neema and Pat, so I'll guess we lost about $30 million in the last quarter. About $98 million for the year.
Click to expand...

Labeling received was ONLY for IV. No oral indication. No nasal indication - however working the grey area the information can be given anyway. Not the blockbuster you thought it would be with your comment about "deterring abuse through all major routes."
 






Yes you're right. Things are unfolding badly. We have no leadership and the company is getting crucified on Wall Street. We're at like $1.38 a share. I'm no financial guy but I'm stunned that Radie hasn't been fired. He's useless, we all hate him.
 






Top Bottom
Back
Quote